The first experience of non-interferon therapy of HCV infection in patients with Wilson-Konovalov's disease.

Autor:	Rozina TP; Faculty of Medicine, M.V. Lomonosov Moscow State University, Moscow, Russia.; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia., Ignatova TM; Faculty of Medicine, M.V. Lomonosov Moscow State University, Moscow, Russia.; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia., Fastovets SV; Faculty of Medicine, M.V. Lomonosov Moscow State University, Moscow, Russia.; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia., Starostina EE; Faculty of Medicine, M.V. Lomonosov Moscow State University, Moscow, Russia., Samokhodskaia LM; Faculty of Medicine, M.V. Lomonosov Moscow State University, Moscow, Russia., Krasnova TN; Faculty of Medicine, M.V. Lomonosov Moscow State University, Moscow, Russia.; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia.
Jazyk:	angličtina
Zdroj:	Terapevticheskii arkhiv [Ter Arkh] 2018 Nov 22; Vol. 90 (11), pp. 74-78.
DOI:	10.26442/terarkh2018901174-78
Abstrakt:	In the article we present three clinical observations demonstrating that HCV infection in patients with remission of Wilson disease causes an recrudescence of the disease, in one of the observations - decompensation of liver cirrhosis. In this study we first describe on the successful treatment of HCV infection with direct antiviral drugs in patients with Wilson disease. Establishment of all factors of liver damage and successful treatment (elimination of the virus, adequate lifelong medical treatment) allow to expect a favorable prognosis in patients with a combination of Wilson disease and HCV infection.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu